Director Dealing

RNS Number : 3514U

Ergomed plc

01 August 2022

 

Director Dealing

Guildford, UK - 1 August 2022 : Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces that on 29 July 2022, Richard Barfield, Chief Financial Officer of Ergomed, sold 25,000 ordinary shares of 1p each in the Company ("Ordinary Shares") at a price of 11.70 per share.

Following this sale, Richard Barfield holds 25,000 Ordinary Shares representing 0.05% of the Company's issued share capital.

The notification set out below is provided in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Richard Barfield
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Ergomed plc
b)	Legal Entity Identifier	213800BVS8I9VMC1AP84
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1 pence each  GB00BN7ZCY67
b)	Nature of the transaction	Sale of Shares
c)	Currency	GBP
d)	Price(s) and volume(s)	Price(s)	Volume(s)
		£11.70	25,000
e)	Aggregated information - Aggregated volume - Price - Aggregated total	25,000 £11.70 £292,500
f)	Date of the transaction	29 July 2022
g)	Place of the transaction	London Stock Exchange, AIM

ENDS

Enquiries :

Ergomed plc       Tel: [phone]

Dr Miroslav Reljanović (Executive Chairman) 

Richard Barfield (Chief Financial Officer) 

Keith Byrne (Senior Vice-President, Capital Markets & Strategy)

Numis      Tel: [phone]

Freddie Barnfield / Euan Brown (Nominated Adviser) 

James Black (Broker) 

Peel Hunt LLP                                                                         Tel: [phone]

James Steel / Dr Christopher Golden

Consilium Strategic Communications                                  Tel: [phone]

Chris Gardner / Matthew Neal                                                  [e-mail]

Angela Gray

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com .

 

END

 

 

DSHGZGFNMMVGZZZ